[[File:MDG Brand RGB.jpg|thumb]]
{{Infobox company
| name              =  Medigene AG
| type              =  Stock company 
| traded_as  = MDG1
| foundation        =  1994
| location          =  [[Martinsried]], [[Germany]]
| key_people        =  Prof Dolores J Schendel (CEO), Dave Lemus (COO), Horst Domdey (Chairman of the supervisory board)
| industry          =  [[Biotechnology]]
| revenue           =  
| operating_income  =  
| net_income        =  
| num_employees     =  
| divisions         =  
| subsid            =  
| homepage          =  {{URL|http://www.medigene.com/}}
| intl              =  yes
}}

'''Medigene AG''' is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit [http://www.medigene.com www.medigene.com]

==References==
http://www.medigene.com

==External links==
{{portal|Companies}}
*{{en icon}}
*{{official website|http://www.medigene.de/}} {{de icon}}

[[Category:Biotechnology companies of Germany]]
[[Category:Pharmaceutical companies established in 1994]]
[[Category:Biotechnology companies established in 1994]]
[[Category:1994 establishments in Germany]]

{{Germany-company-stub}}